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Mycobacteria emulsified in olive 
oil-in-water trigger a robust 
immune response in bladder 
cancer treatment
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Mónica Roldán3, Sandra Guallar-Garrido1, Eduard Torrents4, Marina Luquin1 & Esther Julián1
The hydrophobic composition of mycobacterial cell walls leads to the formation of clumps when 
attempting to resuspend mycobacteria in aqueous solutions. Such aggregation may interfere in the 
mycobacteria-host cells interaction and, consequently, influence their antitumor effect. To improve 
the immunotherapeutic activity of Mycobacterium brumae, we designed different emulsions and 
demonstrated their efficacy. The best formulation was initially selected based on homogeneity and 
stability. Both olive oil (OO)- and mineral oil-in-water emulsions better preserved the mycobacteria 
viability and provided higher disaggregation rates compared to the others. But, among both emulsions, 
the OO emulsion increased the mycobacteria capacity to induce cytokines’ production in bladder 
tumor cell cultures. The OO-mycobacteria emulsion properties: less hydrophobic, lower pH, more 
neutralized zeta potential, and increased affinity to fibronectin than non-emulsified mycobacteria, 
indicated favorable conditions for reaching the bladder epithelium in vivo. Finally, intravesical OO-M. 
brumae-treated mice showed a significantly higher systemic immune response, together with a trend 
toward increased tumor-bearing mouse survival rates compared to the rest of the treated mice. The 
physicochemical characteristics and the induction of a robust immune response in vitro and in vivo 
highlight the potential of the OO emulsion as a good delivery vehicle for the mycobacterial treatment of 
bladder cancer.
Intravesical instillation of Mycobacterium bovis bacillus Calmette-Guerin (BCG) is an effective treatment rou-
tinely used for high-risk non-muscle-invasive bladder cancer (BC) and carcinoma in situ (CIS) patients1. Current 
evidence suggests that BCG therapy prevents recurrence and progression, which prolongs the patient’s survival2,3. 
Although the benefits of BCG immunotherapy are clear, the drawbacks should not be underestimated. The major-
ity of BCG-treated patients do not suffer severe adverse events, but approximately 5% of patients suffer side 
effects that are considered to be serious, and BCG infection cases have been detected4. As part of efforts to seek 
safer alternatives to BCG, we recently demonstrated the antitumor efficacy of the non-pathogenic Mycobacterium 
brumae. M. brumae was initially isolated from soil and water samples in Barcelona (Spain)5,6. No infection cases 
have been described until now either in humans or animals7. Similar to BCG, M. brumae inhibits BC cell growth 
in vitro and in vivo, which triggers an antitumor profile in the immune cells8,9.
The antitumor effect of mycobacteria, however, could be theoretically improved. Mycobacteria cells possess 
a high content of lipids in their cell walls (over 60% of their weight), which provides them with an elevated 
hydrophobic character that leads cells to form clumps of variable size and shape in aqueous solutions10. This 
tendency for clumping makes it difficult to obtain stable and homogeneous mycobacteria suspensions. In fact, 
the BCG aggregates in the usual aqueous solutions that are used for intravesical instillation in BC patients in a 
time-dependent manner, which affects the antitumor activity11,12. Therefore, for an adequate interaction between 
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mycobacteria and target cells, it appears that clumps should be avoided. Thus, obtaining homogenous mycobac-
teria suspensions could influence their antitumor effect.
One of the possible strategies is the formulation of oil-in-water (O/W) or water-in-oil (W/O) mycobacte-
ria emulsions, which have been developed for different types of compounds to enhance the induced immune 
response of antitumor agents or adjuvants13. For example, an O/W preparation of mytomycin, a chemotherapy 
agent that is used for intravesical BC treatment, has recently been conducted to enhance its antitumor effect. The 
microemulsion of mytomycin provides longer stability to the drug (a longer biological half-life) and reduces its 
severe side effects after systemic administration14.
In the case of mycobacteria, researchers who have proposed the use of heat-killed mycobacteria or cell wall 
extracts for cancer treatment or as adjuvants have also developed formulations using oils. In fact, the well-known 
Complete Freund’s Adjuvant (CFA) is a heat-killed preparation of Mycobacterium tuberculosis H37Ra that is 
made by using mineral oil (MO)15. CFA is usually mixed with water-soluble antigens to make W/O emulsions, 
which enhance and prolong the immune response against a mixture of antigens15. Specifically, in all of these cited 
formulations, the used oils were mainly MO and soybean oil (SO), and squalene (SE), a natural organic lipid 
biochemical intermediate in sterol synthesis (Supplementary Table 1). To the best of our knowledge, only one 
previous article reported studying the administration of extracts from killed mycobacteria using olive oil (OO) 
for cancer treatment; however, no formulation was made because the mycobacteria extract was directly resus-
pended using OO16.
In the case of BC, treatment with live mycobacteria is required to obtain an optimum antitumor effect9,8. Thus, 
to improve the antitumor activity of live mycobacteria, we aimed to develop a formulation that can disaggregate 
mycobacteria clumps while ensuring the viability of the mycobacteria. We also aimed to demonstrate the ability 
of this formulation to trigger an proper immune response and to inhibit bladder tumor growth both in vitro and 
in vivo.
Results
O/W emulsion by the rod sonication protocol provided the most homogeneous mycobacteria 
suspension. The initial criterion that was chosen for optimizing the mycobacteria emulsion was based on the 
homogeneity of the suspension and the simplicity of the protocol. Visual inspection showed that there was no 
homogeneity in the emulsions made using the simple sonication protocol or when the W/O emulsions were made 
(Fig. 1a,b). By contrast, when the O/W emulsions were made using the rod sonication protocol, homogeneous 
emulsions were obtained. We also observed that if the mycobacteria were blended with the oil that was already 
mixed with the surfactant, the emulsion was more homogeneous (Fig. 1c).
The OO emulsion maintains the highest proportion of M. brumae viable cells, whereas the MO 
emulsion better disaggregates the M. brumae clumps. After selecting the protocol for making the 
emulsion, we evaluated the affinity of M. brumae for the different tested compounds. As Fig. 2a and Supplemental 
Fig. 1 show, M. brumae has a high tendency to adhere to all lipophilic compounds, indicated by elevated hydro-
phobicity index. The highest affinity of M. brumae was to MO (Fig. 2a), being similar to n-hexadecane, used as a 
positive control17.
Considering that mycobacteria showed a high affinity for all of the compounds studied, we aimed to unravel 
how mycobacteria behave in each of them. When M. brumae viability was studied, we observed that OO main-
tains mycobacteria viability better than the rest, followed by MO emulsion (Fig. 2b, and Fig. 3a,d). By contrast, 
the SO emulsion diminished M. brumae viability to the greatest extent.
Figure 1. Macroscopic appearance of different OO-mycobacteria emulsions. (a) W/O and (b) O/W 
emulsions obtained following the sonication protocol; (c) O/W emulsion following the rod sonication protocol. 
Right tubes (+ ) correspond to M. brumae preparations, and left tubes (–) are without mycobacteria. OO, olive 
oil; W/O, water-in-oil; O/W, oil-in-water.
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With regard to M. brumae clumping, MO was the oil that better disaggregated the mycobacteria clumps, 
obtaining smaller clumps and more isolated cells than the other oils (Fig. 3b,c,e,f). Remarkably, SE emulsified 
M brumae and made the largest clumps, as is clearly seen in the confocal images (Fig. 3c,f).
M. brumae emulsified in OO triggered the highest cytokine production in infected tumor cell 
cultures. After selecting OO and MO since they were best at preserving the mycobacteria viability and dis-
aggregating the clumps, we aimed to demonstrate in vitro the antitumor capacity of emulsified mycobacteria in 
these oils. First, a previously described infection protocol9,18 was optimized to ensure that the emulsion was com-
pletely removed from the culture after washing the cells 3 hours after infection. This goal was confirmed when we 
observed that the cultures treated with the emulsion without mycobacteria (considered the negative control) did 
not affect BC cell proliferation (Fig. 4a,b,c).
As Fig. 4 shows, OO-emulsified mycobacteria inhibited the proliferation of all three BC cell lines to a similar 
degree to non-emulsified mycobacteria. Only in the case of infecting BC cells with OO/W-M. brumae, the inhibi-
tion of MB49 growth was higher than infecting with non-emulsified mycobacteria. Remarkably, MO-emulsified 
mycobacteria were the least efficacious in inhibiting the BC cell proliferation in T24 and MB49 cells (p < 0.05).
Unlike the growth inhibition results, the production of cytokines by infected cells differed clearly between 
infection with emulsified and non-emulsified mycobacteria. As Fig. 4 shows, except for the production of IL-6 in 
MB49 cell culture supernatants after BCG infection, OO/W-mycobacteria triggered significantly higher levels of 
cytokines than the other conditions (p < 0.05). The exception was the 5736 cell line in which no differences were 
detected in cytokine production between infected and non-infected cultures. In fact, this cell line is characterized 
by elevated constitutive levels of cytokine production (Fig. 4f,i), its culture supernatant being used as a source of 
cytokines19.
Emulsified and non-emulsified mycobacteria show similar survival rates inside BC cells. After 
observing in vitro the immunostimulatory superiority of mycobacteria formulated in the OO emulsion, we 
aimed to demonstrate that the formulation does not affect the non-pathogenicity of M. brumae. As Fig. 5 shows, 
M. brumae (both in the emulsion and in PBS) does not persist inside BC cells three-four days after infection, 
whereas BCG remains viable under both conditions.
OO/W-M. brumae would better interact with bladder epithelium than non-emulsified-M. brumae. 
The physicochemical properties could also be crucial, a priori, for a favorable interaction with the bladder epi-
thelium. Thus, different parameters were analyzed. We first observed the reduced capacity of OO/W-M. brumae 
to adhere to polystyrene plates with respect to non-emulsified M. brumae (Fig. 6a), which reflects the reduced 
hydrophobicity of the OO/W-M. brumae. Interestingly, OO/W-M. brumae bound specifically and more effi-
ciently to fibronectin than non-emulsified M. brumae (p < 0.05) (Fig. 6a). OO/W-mycobacteria also showed 
a significantly neutralized zeta potential (Fig. 6b) with respect to non-emulsified mycobacteria. Moreover, the 
emulsion of mycobacteria had a pH of approximately 5 compared with 7.4 obtained when the mycobacteria were 
resuspended in PBS.
We also confirmed the O/W nature of the emulsion by using different techniques. When the OO/W-M. brumae 
was placed into cold water, its behavior corresponded to an O/W emulsion, in which it is completely diluted 
after shaking the plate (Supplementary Fig. 2). We further corroborated the nature of the emulsion by visu-
alization using microscopy techniques (Fig. 6c). Oil droplets containing mycobacteria were clearly observed 
when comparing the images from light and fluorescent microscopy. Moreover, by Field Emission Scanning 
Electron Microscopy (FESEM), high non-uniform spheres with surface holes were observed in the OO/W-M. 
brumae emulsion compared with the small uniform spheres that were observed in the empty emulsion (No-bact) 
Figure 2. Affinity of M. brumae for the different tested compounds and CFU counts in each emulsion. 
(a) The hydrophobicity index was calculated from the means ± SEMs of the absorbance values from triplicate 
preparations of two different experiments. * p < 0.01 versus OO; &p < 0.01 versus MO (Mann-Whitney  
U test). (b) CFU of M. brumae in the different emulsions or in PBS-Tween (Non-E). Values are expressed as  
the mean ± SEM from bacterial culture triplicates of at least three independent experiments. * p < 0.05, versus 
OO-emulsified M. brumae; &p < 0.05 versus MO-emulsified M. brumae (Mann-Whitney U test). OO, olive-oil; 
SO, soybean oil; SE, squalene; MO, mineral oil; nH, n-hexadecane; Non-E, mycobacteria in PBS-Tween.
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(Fig. 6c). It can be observed that in most cases, oil covered one or two mycobacterial cells (Fig. 6c), which con-
firms the results obtained by confocal microscopy (Fig. 3). Finally, no bacilli without oil droplets were observed 
in any sample.
OO/W-mycobacteria elicits a robust immune response in tumor-bearing mice. Finally, we eval-
uated the in vivo activity of OO/W-mycobacteria in the murine orthotopic model of BC. At 9 ± 2 days after tumor 
induction, all of the animals presented hematuria, which is a hallmark of an established tumor9,20. While 100% 
of the non-treated animals died within 40 days of post-tumor implantation, the mycobacteria treatment signif-
icantly prolonged survival in the tumor-bearing mice (p < 0.05). Remarkably, while 83.33% of non-emulsified 
M. brumae-treated mice survived, 100% of the tumor-bearing mice survived after OO/W-M. brumae treatment 
(Kaplan-Meier analysis) (Fig. 7c). With regard to the BCG treatments, only a slight delay in the deaths of the mice 
treated with OO-emulsified BCG were observed with respect to mice that were treated with BCG in PBS. There 
were no significant differences in the survival rates among the mycobacteria-treated groups. Interestingly, no 
M. brumae CFUs were recovered from the spleens of the treated animals. By contrast, BCG CFUs were recovered 
from some of the BCG-treated mice (Fig, 7d), as described previously9.
Figure 3. Viability and aggregation of M. brumae in O/W emulsions. (a) Representative confocal capture 
images of M. brumae emulsified using different compounds, where live bacteria are shown in green (Syto® 
9 staining) and dead bacteria in red (propidium iodide staining). (b) A binary mask representing single 
mycobacteria cells (in blue), small clumps (in purple) and large clumps (in orange). (c) A binary mask 
representing only aggregates. The bars indicate 40 μ m. (d) Mean percentage of live (green columns) and dead 
(red columns) bacteria present in the emulsion with respect to the total counts of green and red bacteria in “a” 
confocal images. (e) Means ± SEMs of the percentage of the area occupied by a single bacterium with respect to 
the total area (in blue) and the area occupied by bacteria forming each type of aggregate (small in purple, and 
large in orange) obtained from the “b” binary mask. * p < 0.01, differences in the percentage of single cells versus 
Non-E; &p < 0.001, differences in the percentage of single cells versus SE (Mann-Whitney U test). (f) Aggregate 
size determined from the “c” binary mask. The median size of the aggregates is indicated on top of each box. 
Error bars indicate range. * p < 0.01 versus Non-E; &p < 0.0001 versus SE (Mann-Whitney U test). Values in ‘d’, 
‘e’ and ‘f ’ were obtained by analyzing 20 fields per condition. OO, olive-oil; SO, soybean oil; SE, squalene; MO, 
mineral oil, Non-E, mycobacteria in PBS-tween; OO-E h-k, olive-oil emulsion of heat-killed M. brumae was 
used as a control.
www.nature.com/scientificreports/
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When the systemic immune response was analyzed, we observed that splenocyte cultures 
from OO/W-mycobacteria treated mice produced higher levels of IFN-γ than splenocytes from 
non-emulsified-mycobacteria treated mice, using either BCG or M. brumae as treatment (p < 0.05) (Fig. 7e). 
This response was specific because no cytokines were detected in supernatant from splenocyte cultures of 
non-mycobacteria treated tumor-bearing mice or healthy mice (Fig. 7e). IL-4 was only detected in splenocyte 
cultures stimulated with Concanavalin A (data not shown).
Images taken from the bladders showed reduced bladder sizes in those obtained from mycobacteria-treated 
mice compared with control mice (Fig. 7b). Histological analyses of the bladders showed that the OO-emulsion 
did not affect the epithelium of the mouse bladder, and no changes were observed compared with the PBS-treated 
group. Non-mycobacteria-treated animals showed a solid mass inside the bladder lumen, with several hemor-
rhagic and necrotic foci in the tumor (Fig. 7b). No tumors were present in mycobacteria-treated bladders. Instead, 
chronic inflammation with moderate to intensive lymphocytic infiltration into the lamina propria and activation 
of the lymphoid follicles were present (Fig. 7b).
Figure 4. Tumor growth inhibition and cytokine production triggered by emulsified or non-emulsified 
mycobacteria. High grade human T24 (a) and murine MB49 (b), and human low grade 5637 (c) BC cells were 
treated with mycobacteria in OO emulsion (white columns), in MO emulsion (gray columns) or in culture 
media (Non-E, black columns). Emulsions without bacteria or cell culture media were added to parallel wells 
(No-bact). In (a–c) results from the MTT assay are shown as the percentage of proliferation in relation to the 
control cells (Non-E No-bact). Data are expressed as the means ± SEMs of the cell culture technical triplicates 
of three independent experiments. IL-6 (d–f) and IL-8/KC (g–i) production by infected and non-infected 
(No-bact) BC cells. Results are shown as the means ± SEMs of two technical replicates of the cell culture 
supernatants. * p < 0.05; * * p < 0.01; * * * p < 0.001; &p < 0.05; &&p < 0.01; &&&p < 0.001 versus the respective 
control No-bact; #p < 0.05; ##p < 0.01 versus the respective BCG (Kruskal-Wallis H test followed by Mann-
Whitney U test). OO, olive oil; MO, mineral oil; Non-E, mycobacteria in PBS-tween; No-Bact, preparations 
without mycobacteria.
www.nature.com/scientificreports/
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Discussion
Mycobacteria are peculiar prokaryotes that are characterized by a highly hydrophobic lipid-rich cell wall. This 
high hydrophobicity is reflected in their tendency to bind to other hydrophobic compounds (Fig. 2a) and to form 
aggregates when they are in a hydrophilic environment. This characteristic means that it is extremely difficult to 
generate aqueous preparations of mycobacteria10,21. Such aggregation could greatly interfere in the interaction 
between host cells and mycobacteria and, consequently, influence their antitumor efficacy. This drawback is espe-
cially important when mycobacteria are used for clinical purposes11,12.
When manipulating mycobacteria for infection studies, different strategies to disrupt the clumps are con-
ducted (i.e., the use of Tween in liquid cultures, glass/metal ball beating, sonication, syringe passes throughout 
narrow needles, among others). However, these methods interfere with mycobacteria viability and/or the loss of 
antigenic molecules from the cell surface22. This point is especially significant for BC treatment because the best 
antitumor action of mycobacteria takes place when live mycobacteria are used8,23–25. Thus, equilibrium between 
the disaggregation of clumps and maintaining mycobacteria viability is desired. Moreover, as is widely known, 
emulsified heat-killed mycobacteria are a potent stimulator of cell-mediated and humoral immune responses15. 
The use of emulsions for heat-killed mycobacteria or cell wall fractions enables the use of these hydrophobic com-
pounds to stimulate the immune system21,26. Due to this crucial relevance in the medical protocols, many different 
oil emulsions have been used for the immunotherapy of cancer (Supplementary Table 1). However, emulsions for 
intravesical live mycobacteria delivery have not been explored until the present work.
Our first relevant result in this work was that among all the mycobacteria emulsions produced, only MO- 
and OO-in-water emulsions efficiently disaggregated the mycobacteria clumps while maintaining mycobacteria 
viability. MO is the main oil that is used to emulsify mycobacteria cell walls (Supplementary Table 1) and is cur-
rently used for intravesical treatment of BC26; however, when the antitumor response in vitro was evaluated, MO 
provided lower inhibition growth proliferation compared with OO-emulsified mycobacteria (Fig. 4). Moreover, 
OO-emulsified mycobacteria triggered the highest production of cytokines in infected tumor cells among all the 
infection conditions assayed (Fig. 4). These cytokines have a partial role in the in vitro inhibition of cell prolifera-
tion18 and, notably, have been related in vivo to the induction of the immune cascade of events inside the bladder 
that leads to the elimination of the tumor23.
Figure 5. BCG and M. brumae survival inside T24, MB49 and 5637 BC cells. Colony-forming units 
(CFUs) from cell lysates at different time-points after infection are represented (h, hours). Values represent the 
means ± SEMs of three serial dilutions of triplicate culture wells of M. brumae infected T24 cells (a), MB49 
cells (b) and 5637 cells (c), and BCG-infected T24 cells (a). Data are representative of one out of three (for T24) 
and two (for MB49 and 5637) independent experiments. BCG counts were estimated from the results obtained 
in the 96-well plate 7H10-based spot assay from dilutions of infected MB49 and 5637 BC cells. & < 0.001 
(Friedman test); * p < 0.05; * * p < 0.01 versus their respective M. brumae. (Kruskal-Wallis H test followed by 
Mann-Whitney U test). Representative pictures of the wells in which grown BCG from MB49 (d) cultures 
and 5637 (e) can be observed. OO-E, olive oil emulsion; MO-E, mineral oil emulsion; Non-E, non-emulsified 
preparation.
www.nature.com/scientificreports/
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Different hypotheses can be formulated to explain the high efficiency of OO-emulsified mycobacteria 
to trigger an immune response at this first step. The first idea that arises is that OO-emulsified mycobacteria 
could be internalized more efficiently than MO and non-emulsified mycobacteria. The internalization of BCG 
is required for IL-6 release by BC cells23,27,28. However, preliminary results obtained in our laboratory indi-
cated that OO-emulsified mycobacteria are successfully internalized inside T24 cells, but to a similar degree 
to non-emulsified mycobacteria (manuscript in preparation), which thus discards the first hypothesis. Second, 
the mechanism of entrance could be different for each emulsion, activating different pathways. The release of 
the mycobacteria inside the cells and/or the presentation of critical antigens could be improved in OO emul-
sions. Further studies are then needed to elucidate the mechanism of mycobacteria uptake by using the different 
vehicles. Finally, we cannot totally discard a synergistic mechanism with the delivery vehicle. Oils have long 
been used as adjuvants, and they are critical for antigen delivery and the interaction of the immunomodulatory 
component/s.
A detailed study of the OO/W emulsion illustrated the affinity of live M. brumae for OO. As early as in 1931, 
Reed and Rice described the attraction of live mycobacteria for OO in oil-water systems29. Moreover, mycobac-
teria possess, as explained earlier, a broad spectrum of lipid and glycolipids in their cell walls, which retain oil 
droplets and stabilize oil-in-water emulsions30. The physicochemical characteristics of OO-emulsified M. brumae 
were also analyzed. Our results showed that OO-emulsified mycobacteria present a lower pH (approximately pH 
5) and hydrophobicity compared with non-emulsified mycobacteria and, although the zeta-potential values were 
still negative, those were closer to neutrality when M. brumae was emulsified (Fig. 6). Intravesical delivery drugs 
should possess pH values of approximately 5, low hydrophobicity, and positive zeta-potential values, to facilitate 
the interaction with the urothelium31,32. These criteria arise because both the bladder luminal side and mycobac-
teria are highly negatively charged in terms of the zeta potential, which results in a low probability of irreversible 
adherence mediated by fibronectin and integrin receptors3,31. Moreover, the mucin layer is hydrophilic, whereas 
the mycobacteria are hydrophobic. Therefore, all three parameters were modified in the emulsified versus 
non-emulsified mycobacteria (Fig. 6), which appears to favor interactions with the urothelium31–33. Finally, bind-
ing to fibronectin, described by several authors as being crucial to an efficient treatment34–36, was increased when 
mycobacteria were in the emulsified form, indicating another advantageous character for efficacious attachment.
Next, the in vivo effect of OO-emulsified mycobacteria in an orthotopic syngeneic mouse model was studied. 
Remarkably, our results showed that 100% tumor-bearing mice survived when treated with OO-M. brumae. 
The high survival rates that were already obtained using non-emulsified M. brumae make it difficult to obtain 
significant differences between the emulsified and non-emulsified M. brumae treated groups without an ele-
vated increase in the number of animals per group, although this option is difficult to justify for ethical rea-
sons. Nevertheless, the high survival rates obtained using OO-M. brumae (100%) have never been achieved 
before with BCG treatment in this animal model9,20. When the systemic immune response triggered by 
Figure 6. Characterization of OO-M. brumae emulsion. (a) Adhesion of M. brumae to BSA-coated (control), 
fibronectin-coated and uncoated (hydrophobicity assay) polystyrene plates. The bars represent means ± SEMs 
of absorbance values of triplicate wells from three independent experiments. &p < 0.05 versus respective BSA-
coated wells; * p < 0.05; * * p < 0.001 (Mann-Whitney U test). (b) Zeta potential of mycobacteria preparations. 
The results are expressed as the mean ± SEM of 20 measurements of each triplicate sample from two 
independent experiments. #p < 0.01 versus OO-E BCG; * p < 0.001 versus Non-E (Mann-Whitney U test). (c) 
Light microscopy (LM): trypan blue and fluorescence staining in upper images and separated canals in bottom 
images, and Field Emission Scanning Electron Microscopy (FESEM) images of OO emulsions with (M. brumae 
OO-E) or without (No-bact OO-E) M. brumae. Bars: 10 μ m in images of LM; in FESEM: 5 μ m, in the general 
views (2 large images), and 1 μ m, in images of the details. OO, olive oil; Non-E, mycobacteria in PBS-tween; 
No-b, No-bact, preparation without bacteria; BSA, Bovine Serum Albumina; Fibron, fibronectin; Hydrofob, 
Hydrofobicity assay.
www.nature.com/scientificreports/
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Figure 7. In vivo treatment with OO-emulsified mycobacteria. (a) Schematic schedule of the induction of the 
tumor and treatments. C57BL/6 mice (n = 6) received four weekly intravesical instillations (indicated by arrows) 
of only the vehicle: emulsion alone (No-bact OO-E) or PBS (No-bact Non-E) or mycobacteria in emulsion 
(OO-E) or in PBS (Non-E), after tumor implantation. (b) On the right, macroscopic pictures taken from 
representative bladders of tumor-bearing mice after receiving the different treatments. Each mark is 1 mm. On 
the left, histological images (hematoxylin-eosin staining) of bladder sections from the same bladders. Scale bar, 
1 mm. (c) Kaplan-Meier curve of survival in tumor-bearing mice after treatments. &p < 0.05 versus respective 
no mycobacteria groups (Log-Rank Mantel-Cox tests). (d) Colony-forming units (CFU) of splenocytes cultures 
from treated mice. The means of three replicates of the viable bacteria from each spleen is represented as a dot; 
the line identifies the mean of the animal group. #p < 0.05 versus respective BCG groups (Mann-Whitney U 
test). (e) Production of IFN-γ by mycobacteria-stimulated splenocytes from treated mice measured 72 hours 
after stimulation. Dots represent the means of two technical replicates per spleen; the line identifies the mean of 
the animal group. &p < 0.05 versus PBS group; * p < 0.05; * * p < 0.01 (Mann-Whitney U test).
www.nature.com/scientificreports/
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emulsified-mycobacteria treated mice was studied, the results showed a significant increase of IFN-γ production 
in spleen cultures (Fig. 7e). The fact that splenocytes specifically restimulated by mycobacteria produce IFN-γ 
means that memory cells are found in the spleen37, driving the shift to a Th1 response that is needed for an effec-
tive treatment25,38. Our results lead us to hypothesize that due to the increased immune response triggered by 
the instillation of emulsified mycobacteria, could enable modifications in the schedule of instillation, providing 
improvements for patients: low number of instillations, reduced dose of bacteria per instillation, more spaced 
instillations or even the duration of the treatment25,39–42. Overall, by administrating OO-emulsified mycobacteria 
it would be possible to find the appropriate pattern of instillations to improve the ratio between therapeutic effi-
cacy and adverse events for the patients, further studies are needed to confirm that point. In fact, the anticancer 
effects of BCG are regulated by complex immune-related mechanisms43. Different authors have described that 
an insufficient immune response or, by contrast, an overactive response are related to inefficient clearance of the 
tumors23. Our current experiments are addressing this point, and the results will provide us with more informa-
tion about the possible clinical efficacy of this treatment.
Outstandingly, our results also demonstrate that emulsified M. brumae is still a non-pathogenic bacterium. 
Neither in vitro (Fig. 5) nor in vivo (Fig. 7d) live emulsified M. brumae cells persist a long time, which confirms its 
non-pathogenicity7,44 and reinforces M. brumae as a safer alternative to BCG for further clinical assays.
Conclusions and future perspectives. In the present study, we demonstrated the improved characteris-
tics of M. brumae emulsified with OO over non-emulsified M. brumae in terms of disaggregating mycobacteria 
clumps while preserving mycobacteria viability, favorable physicochemical properties for in vivo attraction to 
the bladder wall, an innocuous characteristic, and the improved immune response both in in vitro cultures and 
ex vivo from treated tumor-bearing mice. In conclusion, when formulated in olive oil-in-water, emulsified 
M. brumae improves its immunostimulatory capacity for non-invasive bladder cancer treatment.
Materials and Methods
Bacterial strains and cell lines. M. bovis BCG Connaught (ATCC 35745) and M. brumae (ATCC 51384) 
were grown on Middlebrook 7H10 agar (Difco Laboratories, Surrey, UK) supplemented with 10% oleic-albu-
min-dextrose-catalase enrichment medium at 37 °C for 4 and 1 weeks, respectively.
The human transitional carcinoma cell lines T24 and 5637 was kindly provided by the Cancer Cell Line 
Repository (RTICCC-PRBB) and was authenticated following short tandem repeat profiling in DSMZ (most 
recently in September 2014). The mouse BC cell line MB49 was a kind gift from Dr. Mangsbo (Uppsala, Sweden). 
Cell monolayers were maintained as described previously9,18.
The preparation of media, manipulation of samples for instillation into the mice, and culturing procedures 
were always conducted in a biosafety cabinet under sterile conditions.
Preparation of microemulsions. Microemulsions of mycobacteria were prepared following previously 
described protocols (Supplementary Table 1), with slight modifications. Four different compounds, OO, SO, SE 
and MO (all purchased from Sigma-Aldrich, Madrid, Spain), and two different sonication methods were used. 
Thus, in total, 32 different formulations were evaluated (Table 1).
The first sonication protocol that was used consisted of placing 2 mg of mycobacteria dry-weight together with 
the oil phase and then adding the aqueous phase up to a volume of 2 mL in a conical glass tube, which was subse-
quently sonicated in a bath sonicator (BANDERLIN electronic, Berlin, Germany) for 5 minutes at 4 °C45. The sec-
ond sonication method was the rod sonication protocol, which was made in a final volume of 4 mL. For preparing 
the emulsion with the proportions selected (Table 1), 4 mg of mycobacteria (dry-weight) was placed in a sterile 
conical glass tube (Duran Group, Wertheim/Main, Germany), and 47.92 mL of a sterile mixture of 16.52% v/v 
Tween 80 (Sigma-Aldrich) and 83.47% v/v compound was added. Then, a sterile glass rod was used to mix them, 
and 500 μ L of 0.85% w/v NaCl (Panreac, Barcelona, Spain) was added and mixed again. The mixture was soni-
cated in a bath sonicator for 3 minutes at room temperature (RT). The final volume of the emulsion was adjusted, 
and the aqueous phase depended on the bacterial concentration that was required for each experiment46.
Microbial adhesion to hydrocarbons (MATH). To measure the affinity of M. brumae for each of the 
compounds used for the preparation of the emulsions, 0.150 mL of the oil/compound or n-hexadecane (VWR, 
Merck, Barcelona, Spain) was added to 3 mL of M. brumae suspension in PBS (A600 0.44–0.62, referred as A0). 
The mixture was vortexed for 1 minute and settled for 10 minutes. Then, the absorbance of the aqueous phase was 
measured again (A), and the hydrophobicity index was calculated using the following formula: hydrophobicity 
index = [1 − (A/A0) × 100]17,47.
The presence of bacteria in each phase (oil or water) was visualized using three different microscopy tech-
niques (Supplementary Materials and Methods).
Viability and clumping of formulated mycobacteria. M. brumae viability in each emulsion was deter-
mined using two methods: colony-forming unit (CFU) counts and confocal microscopy observation of stained 
live/dead mycobacteria. For the first method, serial dilutions of each emulsion were platted on Middlebrook 
7H10 agar, and the colonies were counted after one week of incubation at 37 °C. For the second method, a LIVE/
DEAD® BacLightTM Bacterial viability kit (Life Technologies, Eugene, OR, US) was used to stain M. brumae in 
each formulation. Stained mycobacteria were observed using a TCS-SP5 confocal laser scanning microscope 
(Leica Microsytems, Mannheim, Germany). HCX PL APO lambda blue 63.0 × 1.40 oil UV objective operating at 
a zoom of 1.8 was used. To determine both the M. brumae viability and the clump size (next paragraph), five hori-
zontal (x-z) optical sections (stepsize 1.51 μ m) of 20 fields for each condition were captured. Digital images were 
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processed with Metamorph software (Molecular Devices LLC, Sunnyvale, CA, US) to calculate the percentage of 
live and dead M. brumae cells.
Masks were applied to the stacks, and the area of the M. brumae clumps formed in each emulsion were ana-
lyzed from the images taken using a confocal microscope, as described above, and were automatically quantified 
using ImageJ software (National Institutes of Health, Bethesda, MD, US). Areas from 0.7 to 3 μ m2 were considered 
to be a single bacterium. Larger areas were considered to be clumps: 3–10 μ m2 were small clumps, and > 10 μ m2 
were large clumps.
Direct growth inhibition experiments and cytokine analysis. T24, MB49 and 5637 bladder tumor 
cells were infected with emulsified and non-emulsified mycobacteria at a multiplicity of infection (MOI) of 10:1, 
and 72 hours post-infection, the cell proliferation was analyzed as described previously9,18. Cytokine produc-
tion on cell culture supernatant was measured using commercially available enzyme-linked immunosorbent 
assay (ELISA) kits according to the manufacturer’s instructions (human IL-8 and IL-6 and mouse IL-6 (BD 
Pharmingen, San Diego, CA, US) and CXCL1/KC (R&D systems, Minneapolis, MN, US)).
Survival of mycobacteria inside bladder cancer cells. T24, MB49 and 5637 BC cells (6 × 104 cells/well) 
were seeded in 48-well tissue culture plates and infected with emulsified or non-emulsified mycobacteria (MOI 
10:1). At different time-points after infection, the supernatants were discarded, and the BC cells were lysed9. Serial 
dilutions of cell lysates were plated on 7H10 plates for CFU counting, as described above, or in a 96-well plate 
7H10-based spot culture growth assay48.
pH and zeta potential of the microemulsions. pH and zeta potential values were determined in 
OO-emulsified and non-emulsified mycobacteria using pH strips and a laser-scattering method (Zetasizer Nano 
ZS, Malvern Instruments, Worcestershire, UK), respectively32.
Adhesion to polystyrene microplate. Fifty microliters of OO-emulsified or non-emulsified mycobacte-
ria were added into BSA-coated (700 μ g/cm2; Millipore-Kankakee, Il, US), fibronectin-coated (1 μ g/cm2; Sigma) 
or non-coated 96-well flat-bottom polystyrene plates in triplicate (Nunc, Roskilde, Denmark). After incubating 
for 24 hours at RT, five washes with PBS were performed. Adhered mycobacteria were stained with 0.05 mL of 
crystal violet (Laboratorios Conda, Madrid, Spain) (1%) for 15 minutes at RT, followed by 5 final washes. The 
absorbance was measured at A550 using an ELISA plate reader. As a negative control, 0.05 mL of PBS was used17.
Visualization of the OO/water emulsion. To confirm the O/W nature of the mycobacteria emulsion, the 
drop test (Supplementary Materials and Methods) and two different microscopy techniques were performed, as 
described previously15. For the light and fluorescent microscopy observation, 2% trypan blue was added to the 
aqueous phase, and the mycobacteria were stained with Syto® 9 (Life Technologies) when performing the emul-
sion in OO. Five microliters of the emulsion was placed on a slide, and the coverslip was sealed with transparent 
nail polish. The samples were observed at 1000X using light and fluorescent microscopes, as described in the 
Supplementary Material and Methods.
To observe the ultrastructure of the emulsified mycobacteria in a near-native stage, a Field Emission Scanning 
Electron Microscope (FESEM) was used. Emulsified and non-emulsified M. brumae were fixed with 1:1 osmium 
tetraoxide (4%, TAAB Lab., West Berkshire, UK) at 4 °C for 30 minutes. Then, 5 μ L samples were deposited in sili-
con wafers (Ted Pella, Redding, CA, US) over a period of 1 minute, and excess sample was blotted with Whatman 
paper, air dried and observed without coating using a FESEM Zeiss Merlin (Oberkochen, Germany) that was 
equipped with a high-resolution in-lens secondary electron detector and operated at 0.8 kV.
Orthotopic model of bladder cancer and intravesical treatment. Animal experiments were 
approved by the Animal Care Committee at the Autonomous University of Barcelona, and were carried out in 
Phase Component
Water-in-oil Oil-in-water
Wu Hwang Yarkoni Morales This work
Polar
6 8 99 98 99
Deionized water 6 8 99 98 99
Tween 80 0.2 0.50
“PBS salts” 0.94
NaCl 0.84 0.84
Apolar
94 92 1 2 1
Oil* 46.0 50.0 1 2 1
Tween 80 18.0 0.2
Span 80 30.0 30.0
Brij 98 12.0
Table 1.  Percentage of hydrophilic and hydrophobic phases and percentage of components in the different 
emulsions used in the literature (Supplementary Table 1) and in this work. * the experiments were performed 
using the four different compounds: olive oil (OO), soybean oil (SO), squalene (SE), and mineral oil (MO). 
Phosphate buffered saline (PBS).
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accordance with the approved guidelines. The orthotopic murine model of BC was developed as described pre-
viously9,20,42,49. Briefly, a tumor was induced in C57Bl/6 female mice (6–8 weeks old; Charles River Laboratories, 
Barcelona, Spain) by intravesically instilling L-poly-lysine (Sigma-Aldrich) followed by 105 MB49 cells. Mice were 
then treated intravesically with mycobacteria (2 × 106 BCG or 2 × 107 M. brumae cells) in PBS or in OO/W emul-
sion (schedule shown in Fig. 7a). Control mice were treated with PBS or emulsion without the mycobacteria. The 
animals were evaluated on a daily basis for their general aspect and behavior and were euthanized when required 
to avoid unnecessary suffering. After 60 days, the surviving animals were sacrificed. The bladders were collected 
and pictures taken; the bladders were then fixed and stained for histopathological examination9. The spleens were 
collected, disrupted, serially diluted in PBS, and plated on 7H10 plates for CFU counting.
Splenocyte cultures. In a second set of experiments (Fig. 7a), mice were sacrificed 29 days after tumor 
induction, spleens were aseptically removed as explained before, and splenocyte cultures were conducted as pre-
viously described50. Triplicate wells were stimulated with 1 mg/mL of heat-killed BCG or M. brumae cells, or 
5 μ g/mL of Concanavalin A (ConA, Sigma) as a positive control. After incubation for 72 hours at 37 °C in 5% 
CO2, pooled supernatants from triplicate wells were collected, centrifuged and frozen until use. Supernatants 
were analyzed for the presence of IFN-γ and IL-4 using commercially available ELISA kits (Mabtech AB, Nacka 
Strand, Sweden).
Statistical analyses. The temporal differences in intracellular CFU in in vitro cell cultures were ana-
lyzed with the non-parametric randomized block analysis of variance for repeated measures Friedman test. 
For multiple comparisons, data were analyzed using the non-parametric one-way analysis of variance by ranks 
Kruskal-Wallis H test. Then, pairwise comparisons were performed using the non-parametric Mann-Whitney 
U test. For comparisons between two groups, data were analyzed using the non-parametric Mann-Whitney U 
test. For all sequential tests, p values were corrected by the Bonferroni adjustment51. For statistical purposes, the 
values below the detection limit were assigned as half of this limit. All these statistical procedures were performed 
using SPSS package version 15.0 for Windows (Chicago, IL, US). Log-Rank (Mantel-Cox) tests determined the 
statistical significance of the Kaplan-Meier survival curves in Prism software version 6.01 for windows (GraphPad 
Prism, La Jolla, CA, US). Differences were considered to be statistically significant when p < 0.05.
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